{"EMN": {"Ticker": "EMN", "Company": "Eastman Chemical", "Sector": "Materials", "Updated": "2022-11-08", "Rating": [{"Date": "2022-11-08", "Rating": "Upgrade", "Organization": "Tudor, Pickering, Holt & Co.", "Rating_Change": "Hold to Buy", "Target_Change": ""}, {"Date": "2022-10-13", "Rating": "Initiated", "Organization": "Goldman", "Rating_Change": "Neutral", "Target_Change": "$78"}, {"Date": "2022-10-11", "Rating": "Initiated", "Organization": "Mizuho", "Rating_Change": "Neutral", "Target_Change": "$116"}, {"Date": "2022-09-14", "Rating": "Downgrade", "Organization": "Wells Fargo", "Rating_Change": "Overweight to Equal Weight", "Target_Change": "$110 to $95"}], "Score": -0.25, "Cumulative_Rating": "Neutral", "Number_of_Analysts": 4, "Period": "180 days", "Letter_Rating": "C", "Analists": ["Tudor, Pickering, Holt & Co.", "Goldman", "Mizuho", "Wells Fargo"], "Price_Target": 96.33}, "MMC": {"Ticker": "MMC", "Company": "Marsh & McLennan", "Sector": "Financials", "Updated": "2022-11-08", "Rating": [{"Date": "2022-11-08", "Rating": "Downgrade", "Organization": "Atlantic Equities", "Rating_Change": "Overweight to Neutral", "Target_Change": "$185"}], "Score": -2.0, "Cumulative_Rating": "Significant Underperform", "Number_of_Analysts": 1, "Period": "180 days", "Letter_Rating": "E", "Analists": ["Atlantic Equities"], "Price_Target": 185.0}, "MTD": {"Ticker": "MTD", "Company": "Mettler Toledo", "Sector": "Health Care", "Updated": "2022-11-08", "Rating": [{"Date": "2022-11-08", "Rating": "Upgrade", "Organization": "Goldman", "Rating_Change": "Sell to Neutral", "Target_Change": "$1120 to $1355"}, {"Date": "2022-09-06", "Rating": "Upgrade", "Organization": "Stifel", "Rating_Change": "Hold to Buy", "Target_Change": "$1500"}], "Score": 1.0, "Cumulative_Rating": "Outperform", "Number_of_Analysts": 2, "Period": "180 days", "Letter_Rating": "B", "Analists": ["Goldman", "Stifel"], "Price_Target": 1427.5}, "VRSK": {"Ticker": "VRSK", "Company": "Verisk Analytics", "Sector": "Industrials", "Updated": "2022-11-08", "Rating": [{"Date": "2022-11-08", "Rating": "Resumed", "Organization": "Morgan Stanley", "Rating_Change": "Equal-Weight", "Target_Change": "$170"}, {"Date": "2022-10-25", "Rating": "Resumed", "Organization": "Jefferies", "Rating_Change": "Buy", "Target_Change": "$230 to $210"}], "Score": 1.0, "Cumulative_Rating": "Outperform", "Number_of_Analysts": 2, "Period": "180 days", "Letter_Rating": "B", "Analists": ["Morgan Stanley", "Jefferies"], "Price_Target": 190.0}, "VTRS": {"Ticker": "VTRS", "Company": "Viatris", "Sector": "Health Care", "Updated": "2022-11-08", "Rating": [{"Date": "2022-11-08", "Rating": "Upgrade", "Organization": "Piper Sandler", "Rating_Change": "Underweight to Neutral", "Target_Change": "$10"}, {"Date": "2022-10-21", "Rating": "Resumed", "Organization": "Jefferies", "Rating_Change": "Hold", "Target_Change": "$11"}], "Score": 0.5, "Cumulative_Rating": "Outperform", "Number_of_Analysts": 2, "Period": "180 days", "Letter_Rating": "B", "Analists": ["Piper Sandler", "Jefferies"], "Price_Target": 10.5}}